Harm Reduction Therapeutics says it plans to produce 2 million doses of 3-milligram naloxone nasal spray, called Rivive, per year.
More Stories
Traders face biggest index rebalancing in four years on Friday: Here’s what to watch for
Investors are facing the busiest quarterly rebalancing in about four years on Friday in a shakeup that could impact roughly...
Four things you need to know about Medicare drug costs and coverage in 2025
With Medicare prescription-drug benefits on the brink of a shake-up, enrollees who hope to minimize their costs at the pharmacy...
Trump Media & Technology Group’s stock hits low as insider stock-sale ban lifts
Trump Media & Technology Group Corp.’s stock dropped to its lowest level since it went public in March Friday, as...
The surprising math of immigration, Social Security and Medicare
Immigration will have an effect on your retirement — but it’s probably not what you think.
New York’s pot business on track to join $1 billion legal state sales club
New York State may approach $1 billion in legal pot sales this year as its legal cannabis business gains traction...
Nike’s stock has been dogged by these issues. Can a new CEO change the game?
New Nike CEO Elliot Hill is inheriting “a turnaround that has yet to show momentum,” according to Stifel analyst Jim...